A Strategy for Selective O 6-Alkylguanine-DNA Alkyltransferase Depletion Under Hypoxic Conditions

Chemical Biology and Drug Design

Volumn 80, Issue 2, 2012, Pages 279-290

  Penketh, Philip G ^a   Shyam, Krishnamurthy ^a   Baumann, Raymond P ^a   Ishiguro, Kimiko ^a   Patridge, Eric V ^a   Zhu, Rui ^a   Sartorelli, Alan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Nitro 6 benzyloxypurine; Chemotherapy; Hypoxia; O 6 alkylguanine DNA alkyltransferase; O 6 benzylguanine; Prodrug; Sensitization; Targeting

Indexed keywords

2 NITRO 6 BENZYLOXYPURINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; CYTOCHROME P450 REDUCTASE; LAROMUSTINE; SILVER CHLORIDE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ARTICLE; HUMAN; HUMAN CELL; HYPOXIA; OXYGEN CONCENTRATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE; ENZYME INHIBITORS; GUANINE; HL-60 CELLS; HUMANS; HYDRAZINES; HYDROGEN PEROXIDE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OXIDATION-REDUCTION; OXYGEN; PURINES; SULFONAMIDES; SUPEROXIDES;

EID: 84864013772     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01401.x     Document Type: Article

References (39)

1. Gerson S.L. (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol;20:2388-2399.
2. Pegg A.E., Dolan M.E., Moschel R.C. (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. In: Cohn W.E., Moldave K., editors. Progress in Nucleic Acid Research and Molecular Biology. San Diego: Academic Press, 51; p. 167-223.
3. 6-alkylguanine-DNA alkyltransferase from human leukemic cells. Prevention of chloroethylnitrosourea-induced cross-links by purified enzyme. Pharmacol Ther;31:121-140.
4. Yan L., Bulgar A., Donze J., Liu L. (2004) Inactivation of AGT involved in extracellular signal pathway to regulate cell proliferation. Proc Am Assoc Cancer Res;45:abstract # 3489.
5. 6-alkylguanine DNA alkyltransferase. Protein Sci;13:301-305.
6. Ribrag V., Massaad L., Janot F., Bissery M.C., Parise O. Jr, Gouyette A., Chabot G.G. (1994) Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res;18:829-835.
7. Larminat F., Germanier M., Papouli E., Defais M. (2002) Deficiency in BRCA2 leads to increase in non-conservative homologous recombination. Oncogene;21:5188-5192.
8. Ishiguro K., Seow H.A., Penketh P.G., Shyam K., Sartorelli A.C. (2006) Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther;5:1-8.
9. 6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther;4:1755-1763.
10. Finch R.A., Shyam K., Penketh P.G., Sartorelli A.C. (2001) 1, 2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res;61:3033-3038.
11. Johnston T.P., Montgomery J.A. (1986) Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems. Cancer Treat Rep;70:13-30.
12. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol;20:2277-2283.
13. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res;6:3025-3031.
14. 6-alkylguanine transferase (AGT) levels in patients (pts) with hematologic malignancies receiving VNP40101M (101M). ASCO Annual Meeting: Abstract #6542.
15. Wardman P. (1985) Some reactions and properties of nitro radical-anions important in biology and medicine. Environ Health Perspect;64:309-320.
16. 6-alkylguanine-DNA alkyltransferase. Mutat Res;460:151-163.
17. Shyam K., Penketh P.G., Divo A.A., Loomis R.H., Patton C.L., Sartorelli A.C. (1990) Synthesis and evaluation of 1, 2, 3-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem;33:2259-2264.
18. Bianco P., Haladjian J. (1977) Study of two forms of ferredoxin from Desulfovibrio gigas by differential pulse polarography. Biochem Biophys Res Commun;78:323-327.
19. Weiss R.F. (1970) The solubility of nitrogen, oxygen and argon in water and seawater. Deep Sea Res Oceanograp Abst;17:721-735.
20. Miller R.T., Martásek P., Roman L.J., Nishimura J.S., Masters B.S.S. (1997) Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry;36:15277-15284.
21. Baumann R.P., Penketh P.G., Seow H.A., Shyam K., Sartorelli A.C. (2008) Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res;170:651-660.
22. Penketh P.G., Shyam K., Baumann R.P., Remack J.S., Brent T.P., Sartorelli A.C. (2004) 1, 2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol;53:279-287.
23. Penketh P.G., Shyam K., Sartorelli A.C. (1997) Fluorometric assay for the determination of DNA-DNA cross-links utilizing Hoechst 33258 at neutral pH values. Anal Biochem;252:210-213.
24. 6-benzylguanine to the protein. Anal Biochem;383:44-51.
25. Baumann R.P., Seow H.A., Shyam K., Penketh P.G., Sartorelli A.C. (2005) The antineoplastic efficacy of the prodrug cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res;15:313-325.
26. Baumann R.P., Penketh P.G., Ishiguro K., Shyam K., Zhu Y.L., Sartorelli A.C. (2010) Reductive activation of the prodrug 1, 2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O6-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance. Biochem Pharmacol;79:1553-1561.
27. Rockwell S. (1977) In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab Anim Sci;27:831-851.
28. Belcourt M.F., Hodnick W.F., Rockwell S., Sartorelli A.C. (1998) The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem;273:8875-8881.
29. 6-Alkylguanine-DNA alkyltransferase. Biochem Pharmacol;80:1317-1325. PMCID:PMC2950702.
30. Greenstock L., Ruddock G.W., Neta P. (1976) Pulse radiolysis and ESR studies of the electron-affinic properties of nitroheterocyclic radiosensitizers. Radiat Res;66:472-484.
31. Bennewith K.L., Raleigh J.A., Durand R.E. (2002) Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res;62:6827-6830.
32. Koh W.J., Rasey J.S., Evans M.L., Grierson J.R., Lewellen T.K., Graham M.M., Krohn K.A., Griffin T.W. (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys;22:199-212.
33. Tatsumi K., Inoue A., Yoshimura H. (1981) Mode of reactions between xanthine oxidase and aromatic nitro compounds. J Pharmacobiodyn;4:101-108.
34. Oliveira I.M., Bonatto D., Henriques J.A. (2010) Nitroreductases: enzymes with environmental, biotechnological and clinical importance. In: Méndez-Vilas A. (editor) Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology. Spain: Formatex Badajoz, 2; p. 1008-1019.
35. 6-alkylguanine-DNA alkyltransferase (AGT) which produces resistance to agents targeting the O-6 position of DNA guanine. J Med Chem;54:7720-7728.
36. Minchinton A.I., Tannock I.F. (2006) Drug penetration in solid tumours. Nat Rev Cancer;6:583-592.
37. Stohrer M., Boucher Y., Stangassinger M., Jain R.K. (2000) Oncotic pressure in solid tumor is elevated. Cancer Res;60:4251-4255.
38. Hicks K.O., Secomb T.W., Pruijn F.B., Hay M.P., Hsu R., Brown J.M., Denny W.A., Dewhirst M.W., Wilson W.R. (2006) Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst;98:1118-1128.
39. McElhinney R.S., Donnelly D.J., McCormick J.E., Kelly J., Watson A.J., Rafferty J.A., Elder R.H., Middleton M.R., Willington M.A., McMurry T.B., Margison G.P. (1998) Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem;41:5265-5271.